Article

Oncological outcomes in 2004: report from the Cancer Registration Committee of the JUA

The Cancer Registration Committee of the Japanese Urological Association, and Urology Division, National Cancer Center Hospital, Tokyo, Japan.
International Journal of Urology (Impact Factor: 2.41). 12/2011; 18(12):876-81. DOI: 10.1111/j.1442-2042.2011.02895.x
Source: PubMed

ABSTRACT

In 2001, the Cancer Registration Committee of the Japanese Urological Association initiated a data collection of prostate cancer patients into a computer-based database. The aim of the present study is to report the clinical and pathological characteristics and outcomes of prostate cancer patients diagnosed in 2004 in Japan.
Overall, 11,385 patients from 239 institutions were registered into the database. After excluding 1105 patients because of insufficient data, duplication or insufficient follow up, 10,280 patients were eligible for the analysis. Most of them (10,198, 99.2%) were Japanese and 1195 (11.6%) had metastatic disease at the time of diagnosis. The mean and median follow up was 53.2 months and 61.5 months, respectively.
The 5-year overall and prostate cancer-specific survival rate was 89.7% and 94.8%, respectively. The 5-year prostate cancer-specific survival rate of M0 and M1 disease was 98.4% and 61.1%, respectively. For 8424 cases of organ-confined or regional disease, Japanese urologists used as the initial treatment hormone ablation therapy alone (3360, 39.9%), radical prostatectomy (3140, 38.1%), radiation therapy (1530, 18.2%) and watchful waiting (394, 4.7%) including active surveillance or palliative observation.
This is the first large population report of survival data in Japanese prostate cancer patients. In Japan, the disease population, survival period with metastatic disease and ratio of patients having hormone ablation therapy differ from those in Western countries.

Download full-text

Full-text

Available from: Tsuneharu Miki, Oct 14, 2014
  • Source
    • "Half of the patients showed high risk features and received PADT according to this report. This result was compatible with reports by the Japanese Urological Association (JUA) [3,6] that 57% and 50% of patients received PADT in 2000 and 2004, respectively. We concluded that the higher use of PADT and the higher proportion of high risk patients were distinctive trends among Japanese prostate cancer patients compared with those in the USA [2,7,8]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: To assess the trends of risk classification and primary therapy in Japanese patients who were diagnosed with prostate cancer between 2004-2006 and 2007-2009. A total of 4752 patients who were newly diagnosed with prostate cancer at Nara Medical University and its 23 affiliated hospitals between 2004 and 2009 were enrolled. The differences in risk classification and primary therapy were compared in patients who were newly diagnosed between 2004-2006 (prior period) and 2007-2009 (latter period). The proportion of patients with a high or greater risk significantly decreased in the latter period compared to the prior period (p < 0.001). The proportion of primary androgen deprivation therapy (PADT) was 50% in the prior period, and 40% in the latter period. On the other hand, the proportion of radiation therapy was 14% in the prior period, but 24% in the latter period. The proportion of radical prostatectomy was the same in the two periods (30%). The primary therapy was significantly different between the two periods (p < 0.001). Higher risk patients significantly decreased in the latter period compared to the prior period. The use of PADT also significantly decreased in the latter period. However, there were still higher risk patients in Japan, and the use of PADT was still common in patients with localized prostate cancer or locally advanced prostate cancer in Japan.
    Full-text · Article · Dec 2013 · BMC Cancer
  • Source
    • "Third, considerable bias exists in cancer-articles. Surgery is a major treatment option for prostate cancer in Japan [7]. More than half of prostate cancer articles were, however, on radiotherapy because a famous radiologist was in charge of serial column. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Little information on cancer coverage rather than newspaper and television is available. Japanese weekly magazines have a circulation of over 2,700,000 per week. To examine how they delivered urogenital cancer information to the public, cancer-related articles and advertisements in six major Japanese weekly magazines from 2009 to 2010 was ana-lyzed. 1.8% of total articles and advertisements were cancer-related. Prostate cancer (n = 119) was the second-most common topic, following lung cancer (n = 145), whereas only three articles were published on kidney or bladder cancer. The 53 articles on therapies for prostate cancer comprised radiotherapy (n = 29), surgery (n = 16), chemotherapy (n = 4), and others (n = 4). All 42 comments or interviews were cited in the article on prostate cancer, while 26 of them were attributed to only two famous doctors. Although cancer coverage in weekly magazines could be useful to spread infor- mation on prostate cancer, we should recognize their considerable bias based on a disproportionate emphasis.
    Full-text · Article · Oct 2013 · Open Journal of Urology
  • Source
    • "Third, considerable bias exists in cancer-articles. Surgery is a major treatment option for prostate cancer in Japan [7]. More than half of prostate cancer articles were, however, on radiotherapy because a famous radiologist was in charge of serial column. "

    Full-text · Article · Jan 2013 · Open Journal of Urology
Show more